Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

AIM WINNERS & LOSERS: NetScientific surges on Astra Covid test pact

7th Jun 2021 10:38

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

NetScientific PLC, up 36% at 102.00 pence, 12-month range 102.00p-4.62p. Subsidiary ProAxsis Ltd enters exclusive licensing agreement with FTSE 100-listed AstraZeneca PLC. ProAxsis will take responsibility for completing the validation and global commercialisation of a SARS-CoV-2 serology enzyme-linked immunosorbent assay developed by internal research team at AstraZeneca. "In return for providing access to the required intellectual property and technical know-how, AstraZeneca will receive an undisclosed royalty fee on future global net sales of the assay," it says.

----------

EPE Special Opportunities Ltd, up 8.4% at 375.00p, 12-month range 380p-155p. Hits this 12-month high earlier on Monday. The investment company says that its EPIC Investments LLP sells 4.5 million shares in Luceco PLC, worth GBP15.0 million. Shares sold represent 11% of firm's interest in Luceco, and it plans to use the proceeds for new investments. Luceco shares trading up 3.0% at 358.5p.

----------

Directa Plus PLC, up 8.3% at 130.00p, 12-month range 59p-160p. The producer of graphene nanoplatelets-based products says its customer NexTech Batteries Inc has formed a wholly owned Italian subsidiary, NexTech Italia SpA, with initial objective to evaluate feasibility of producing cathode active materials in Italy, using Directa Plus's G+ graphene nanoplatelets, for the manufacture of Lithium-Sulphur batteries throughout Europe. "This is a key building block in laying the foundation for strategic growth. We will work together with existing partners of Directa Plus, located in several countries across the European Union, to support the development of Lithium-Sulphur batteries in Europe," says Directa Plus Founder & Chief Executive Giulio Cesareo.

----------

Scancell Holdings PLC, up 8.1% at 21.35p, 12-month range 5.01p-29p. Says Vulpes Life Sciences Fund, which is closely associated with Non-Executive Martin Diggle, buys 400,000 shares at 19.25p each, worth GBP77,000. This takes Vulpes's total interest to 117.0 million shares, representing just over 14% stake in Scancell.

----------

AIM - LOSERS

----------

Steppe Cement Ltd, down 13% at 45p, 12-month range 21p-55.25p. The Kazakhstan-focused construction materials firm says revenue in 2020 slips 6% to USD74.8 million from USD79.9 million in 2019, though pretax profit rises 5% to USD13.1 million from USD12.5 million. Profit improvement driven by lower finance costs and a jump in 'other' income.

----------

DeepVerge PLC, down 7.4% at 31.49p, 12-month 16.6p-70p. The life science company conditionally raises GBP10 million via placing of 31.5 million shares and subscription for 1.8 million shares, at price of 30p each. Price represents discount of 12% to Friday's closing price. "This fundraising enables the Company, on three continents, to scale, to meet increased demand, while expanding revenues faster across the Group," says Chief Executive Gerry Brandon.

----------

By Lucy Heming; [email protected]

Copyright 2021 Alliance News Limited. All Rights Reserved.


Related Shares:

Directa PlusNetscientificEpe Special OppSteppe CementScancell HoldingsDVRG.L
FTSE 100 Latest
Value8,809.74
Change53.53